Physician profile
Jonathan Hendrie
NPI 1700444965
$3,360.37
in general payments reported to CMS, 2019-2025
20 companies · $2,251 in 2025
The $2,251 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,109 · 2025: $2,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.39 |
| Education | $177.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $963.20 | 2024-2025 | Krystexxa, Evenity, Uplizna |
| Janssen Biotech, INC. | $491.65 | 2024-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $389.28 | 2024-2025 | |
| Ucb, INC. | $239.44 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $208.19 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $155.38 | 2024-2025 | Saphnelo |
| Genzyme Corporation | $149.19 | 2024-2025 | |
| Glaxosmithkline, LLC. | $129.57 | 2024-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $103.08 | 2024-2025 | Orencia |
| Sobi, INC | $87.29 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $86.70 | 2024 | |
| Alexion Pharmaceuticals, INC. | $73.61 | 2024-2025 | Strensiq, Ultomiris |
| Aurinia Pharma U.S., INC. | $55.88 | 2024-2025 | Lupkynis |
| Octapharma USA, INC. | $50.25 | 2024-2025 | Octagam Immune Globulin (Human) |
| Mallinckrodt Hospital Products INC. | $41.99 | 2025 | Acthar |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $38.27 | 2025 | Tymlos |
| Organon LLC | $33.53 | 2024-2025 | Renflexis, Hadlima |
| Invivyd INC | $26.57 | 2025 | Pemgarda |
| Kyowa Kirin, INC. | $20.39 | 2025 | |
| Lilly USA, LLC | $16.91 | 2024 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hendrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.